1. Introduction {#sec1}
===============

Hyperglucagonemia is present in type 1 [@bib1], [@bib2] and type 2 [@bib3], [@bib4] diabetes and contributes to elevated blood glucose by stimulating glycogenolysis, gluconeogenesis, and ketogenesis, while suppressing glycogen synthesis. Moreover, suppression of glucagon action by glucagon receptor (Gcgr) gene deletion, glucagon immunosuppression, or Gcgr antagonist can ameliorate diabetic symptoms in models of both type 1 and type 2 diabetes. To investigate the effect of suppressing glucagon action in a model of insulinopenic diabetes, Gcgr wildtype (WT) and knockout (KO) mice were injected with the β-cell toxin streptozotocin (STZ) [@bib5], [@bib6]. GcgrWT mice become hyperglycemic, hyperketonemic, polyuric, and cachectic, while, remarkably, GcgrKO mice were protected from these diabetic symptoms [@bib5], [@bib6]. In addition, immunoneutralization of glucagon using a monoclonal antibody reduced hyperglycemia in alloxan-diabetic rabbits [@bib7]. Moreover, in STZ-injected mice, weekly treatment with a Gcgr antibody completely normalized blood glucose levels for up to 12 weeks, concomitant with an improvement in HbA1c levels [@bib8]. Similarly, immunoneutralization of endogenous glucagon improved oral glucose tolerance and reduced hepatic glucose output in obese leptin-deficient *ob/ob* mice [@bib9], and Gcgr antisense oligonucleotides or small interfering RNA (siRNA) diminished hyperglycemia and improved oral glucose tolerance in obese leptin receptor null *db/db* mice [@bib10], [@bib11]. Finally, genetic deletion of Gcgr in diet-induced obese mice or *db/db* mice prevented obesity, hyperinsulinemia, and hyperglycemia [@bib12]. Therefore, inhibiting glucagon action can improve diabetic symptoms in various models of diabetes.

The hormone leptin, well known for its role in body weight regulation, has also shown promise as a glucose-lowering therapy. In rodent models of type 1 diabetes, leptin monotherapy can potently reduce diabetic symptoms and normalize hyperglycemia [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20]. Interestingly, leptin can reduce circulating glucagon levels and levels of hepatic p-CREB indicative of reduced Gcgr signaling [@bib13], [@bib14], [@bib16], which has been thought to be important for the glucose-lowering mechanism of leptin. Moreover, in STZ-diabetic rodents, intracerebroventricular leptin reduces preproglucagon mRNA levels in the pancreas, glucagon content in the pancreas [@bib15], and plasma glucagon levels [@bib21], suggesting that leptin can act through the central nervous system to suppress glucagon production. However, in type 2 diabetes, leptin monotherapy appears to be less efficacious as an anti-diabetic therapy. Although leptin injections in a rat model of obese type 2 diabetes normalized fasting blood glucose [@bib22], leptin treatment in humans with type 2 diabetes did not increase insulin-mediated stimulation of glucose disposal [@bib23] nor meaningfully reduce HbA1c [@bib24]. The failure of leptin to improve type 2 diabetes may be due to leptin resistance as many obese individuals are hyperleptinemic [@bib25].

In this report, we investigated the efficacy of Gcgr siRNA delivered using lipid nanoparticle (LNP) technology and compared this treatment to leptin therapy in mouse models of type 1 and type 2 diabetes. LNPs are capable of effectively and safely delivering genetic drugs such as siRNA to target tissues, and they are the most clinically advanced delivery systems for siRNA, with multiple LNP-siRNAs in clinical trials for the treatment of various diseases [@bib26]. In addition, LNPs effectively target the liver [@bib27], [@bib28], where glucagon exerts most of its biological functions. Indeed mice with full-body or hepatocyte specific *Gcgr* gene deletion display a similar degree of improvement of fasting blood glucose levels and glucose tolerance highlighting the importance of glucagon action on the liver in regulating glucose metabolism [@bib29], [@bib30]. We find that Gcgr siRNA can potently improve glucose metabolism in both STZ (a model of type 1 diabetes) and high fat diet (HFD)/STZ (a model of type 2 diabetes) diabetic mice. However, while leptin was able to improve both glucose and lipid metabolism in STZ-diabetic mice, no changes were observed in HFD/STZ-diabetic mice given leptin treatment.

2. Research design and methods {#sec2}
==============================

2.1. Animals {#sec2.1}
------------

Male C57BL/6J mice (stock 000664), C57BL/6J mice on 60% HFD (stock 380050) or C57BL/6J mice on 10% low fat diet (LFD) (stock 380056) were obtained from the Jackson Laboratory (Bar Harbor, ME, USA) and acclimatized on arrival for at least a week. Mice were housed on a 12-h:12-h light--dark cycle with *ad libitum* access to normal chow (Harlan Laboratories, \#2918, Indianapolis, IN, USA), 60% HFD (Research Diets, Inc., D12492i, New Brunswick, NJ, USA) or 10% LFD (Research Diets, Inc., D12450Bi, New Brunswick, NJ, USA) and water. All experiments were approved by the University of British Columbia Animal Care Committee and carried out in accordance with the Canadian Council on Animal Care guidelines.

2.2. Generation of STZ-diabetic mice {#sec2.2}
------------------------------------

STZ (Sigma--Aldrich, Oakville, Canada) was prepared in a pH 4.5 acetate buffer and 180 mg/kg STZ was administered i.p. to 9 week old C57BL/6J mice. Non-diabetic controls received an i.p. injection of acetate buffer alone.

2.3. Generation of HFD/STZ-diabetic mice {#sec2.3}
----------------------------------------

C57BL/6J mice were put on a 60% HFD (Research Diets, Inc., D12492i, New Brunswick, NJ, USA) at 6 weeks of age and remained on the diet until the end of the study. At 10 weeks of age, STZ (Sigma--Aldrich, Oakville, Canada) was prepared in a pH 4.5 acetate buffer and administered at a dose of 100 mg/kg. Controls were put on a 10% LFD (Research Diets, Inc., D12450i, New Brunswick, NJ, USA) at 6 weeks of age and did not receive an i.p. injection of acetate buffer.

2.4. Preparation and delivery of LNP-siRNA {#sec2.4}
------------------------------------------

siRNAs were purchased from Integrated DNA Technologies (Coralville, IA, USA); sequences are in [Supplemental Table 1](#appsec1){ref-type="sec"}. LNP-siRNA systems were prepared as previously described [@bib31]. For all studies, siRNA was delivered via the tail vein. Either 5 mg/kg or 10 mg/kg LNP encapsulating Gcgr siRNA 2 or 10 mg/kg LNP encapsulating an equal mix of Gcgr siRNA 1 and 2 were injected. LNP encapsulating FVII siRNA was injected at the same total dose of GCGR siRNA for each study.

2.5. Leptin therapy {#sec2.5}
-------------------

STZ-diabetic mice at 10 weeks of age received 20 μg/day of recombinant mouse leptin (Peprotech, Rocky Hill, NJ, USA) prepared in sterile water and administered via Alzet 1004 mini-osmotic pumps (DURECT Corporation, Cupertino, CA, USA). HFD/STZ-diabetic mice at 12 weeks of age received 20 μg/day PEG-ylated leptin (Protein Laboratories Rehovot Ltd., Rehovot, Israel) prepared in sterile water by daily i.p. injection while control HFD/STZ mice received water (vehicle).

2.6. Plasma analyte analysis {#sec2.6}
----------------------------

All blood parameters were measured using samples collected from 4 h fasted mice. Hemoglobin A1c (HbA1c) levels were measured using a Siemens DCA 200 Vantage Analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY, USA) from whole blood. Plasma insulin (Mouse Ultrasensitive Insulin ELISA, ALPCO, Salem, NH, USA), glucagon (Glucagon ELISA, Mercodia, Salem, NC, USA), leptin (Mouse Leptin ELISA, Crystal Chem, Downers Grove, IL, USA), β-hydroxybutyrate (β-Hydroxybutyrate LiquiColor Test, Stanbio, Boerne, TX, USA), free fatty acids (HR Series NEFA HR\[2\] Kit, Wako Diagnostics, Richmond, VA, USA), triglycerides and glycerol (Serum Triglyceride Determination Kit, Sigma--Aldrich, Oakville, Canada), and cholesterol (Cholesterol E, Wako Diagnostics, Richmond, VA, USA) were measured from cardiac puncture blood samples. For samples from PEG-leptin injected mice, plasma leptin levels were analyzed using a PEG-leptin standard curve as the PEG-leptin was less potent in the assay than an equivalent amount of normal leptin.

2.7. Oral glucose tolerance tests {#sec2.7}
---------------------------------

Mice were fasted for 4 h and given oral gavages of either 1.5 g/kg of 30% dextrose or 2 g/kg of 50% dextrose. Blood glucose was measured via the saphenous vein using a One Touch Ultra Glucometer (LifeScan) with a detection limit of 1.1--33.3 mM. During the oral glucose tolerance tests, if samples fell over the detection limit they were diluted with non-diabetic blood of known glucose concentration, re-assayed, and original blood glucose levels were calculated. Area under the curve (AUC) was measured starting at baseline (0 min) values.

2.8. Immunofluorescence and analysis of α-cell area {#sec2.8}
---------------------------------------------------

Pancreata were harvested from mice on day 7, fixed overnight in paraformaldehyde at 4°C, rinsed in 70% ethanol, embedded in paraffin, and sectioned by Wax-it Histology Services Inc. (5 μm thickness; Vancouver, BC, Canada). The antibodies used are detailed in [Supplemental Table 2](#appsec1){ref-type="sec"}. Cell nuclei were counterstained with VECTASHIELD HardSet Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA, USA). Whole slide fluorescence scanning was performed using the ImageXpress Micro Imaging System (Molecular Devices Corporation, Sunnyvale, CA, USA). Individual images were stitched together to recreate the pancreas area and then quantified using MetaXpress software. For α-cell area, glucagon positive area was expressed relative to the pancreas area; 3 sections were quantified per animal, separated by 200 μm.

2.9. Statistics {#sec2.9}
---------------

Data are presented as either mean ± SEM or min to max box and whisker plots (where the box extends to the 25th and 75th percentiles, the middle line is the median, and the whiskers extend to the minimum and maximum values). Data were analyzed using a 1-way or 2-way ANOVA for bar and line graphs, respectively with Dunnett or Tukey post-hoc testing. Statistical analysis was performed using GraphPad Prism 6.05 (La Jolla, CA, USA) and significance was set at P \< 0.05.

3. Results {#sec3}
==========

3.1. Gcgr siRNA lowers blood glucose and improves oral glucose tolerance in wildtype mice {#sec3.1}
-----------------------------------------------------------------------------------------

To identify an effective Gcgr siRNA, one of 3 Gcgr siRNAs or FVII siRNA used as a control were encapsulated into LNPs and delivered via the tail-vein to wildtype mice at a dose of 5 mg/kg, and glucose homeostasis was assessed. A group of mice receiving PBS served as a control and demonstrated that the particles themselves had no effect on the parameters measured ([Figure 1](#fig1){ref-type="fig"}). None of the Gcgr siRNAs affected body weight ([Figure 1](#fig1){ref-type="fig"}A). Strikingly, despite the mice already being healthy, Gcgr siRNA 1 and 2 lowered fasting blood glucose levels (8.8 ± 0.4 mM PBS, 8.1 ± 0.3 mM FVII siRNA, 5.1 ± 0.2 mM Gcgr siRNA 1, 5.6 ± 0.1 mM Gcgr siRNA 2, 8.1 ± 0.4 mM Gcgr siRNA 3, day 7, P \< 0.05, [Figure 1](#fig1){ref-type="fig"}B) and reduced blood glucose levels throughout an oral glucose tolerance test, while Gcgr siRNA 3 had no effect ([Figure 1](#fig1){ref-type="fig"}C). However, glucose excursion as measured by AUC from baseline was not statistically different than controls ([Figure 1](#fig1){ref-type="fig"}D). In addition, Gcgr siRNA 1 and 2 but not 3 caused an elevation in circulating glucagon levels (21 ± 6 pg/mL PBS, 14 ± 3 pg/mL FVII siRNA, 91 ± 2 pg/mL Gcgr siRNA 1, 140 ± 30 pg/mL Gcgr siRNA 2, 36 ± 13 pg/mL Gcgr siRNA 3, P \< 0.05, [Figure 1](#fig1){ref-type="fig"}E) without a corresponding increase in α-cell area ([Figure 1](#fig1){ref-type="fig"}F). Notably, our acute knockdown model exhibited a similar phenotype to mice with a lifelong, full-body knockout of the Gcgr, which also display reduced blood glucose levels, improved glucose tolerance, and increased glucagon levels [@bib29]. In a separate cohort, hepatic Gcgr mRNA levels were quantified on day 2. In agreement with the phenotypic data, mice receiving Gcgr siRNA 1, 2, and 3 had average *Gcgr* transcript levels of 37%, 30%, and 109%, respectively, of those seen in FVII controls respectively; however, this did not reach significance due to variability and low sample size in the FVII group ([Supplemental Figure 1](#appsec1){ref-type="sec"}). Based on the trends observed with *Gcgr* mRNA levels and robust phenotypic data, we chose either Gcgr siRNA 2 or a combination of Gcgr siRNA 1 and 2 for continuing our studies in diabetic models.Figure 1**Gcgr siRNA reduces blood glucose, improves oral glucose tolerance, and increases plasma glucagon without affecting α-cell area in wildtype mice.** Mice received Gcgr siRNA or FVII siRNA at a dose of 5 mg/kg or PBS on day 0. Body weight (A) and blood glucose (B) were measured throughout the study. On day 6, an oral glucose tolerance test was performed using 2 g/kg of 50% dextrose (C), and area under the curve (AUC) from baseline was calculated (D). Plasma glucagon (E) and α-cell area (F) were analyzed on day 7. Each group was compared to the FVII siRNA treated group by 1- or 2-way ANOVA with Dunnett post-hoc testing; a, P \< 0.05 Gcgr siRNA 1 vs FVII siRNA; b, P \< 0.05 Gcgr siRNA 2 vs FVII siRNA. Data are mean ± SEM (A--C) or min to max box and whisker plots (D--F), n = 4.Figure 1

3.2. 5 mg/kg Gcgr siRNA does not improve glucose and lipid metabolism as effectively as leptin therapy in STZ-diabetic mice {#sec3.2}
---------------------------------------------------------------------------------------------------------------------------

Next we sought to determine whether Gcgr siRNA could improve diabetic symptoms in a model of diabetes and to compare this treatment to leptin, which is a potent glucagon suppressor and can normalize blood glucose levels in mouse models of diabetes [@bib13], [@bib14], [@bib15], [@bib16], [@bib20]. Diabetes induced by 1 or 2 high dose STZ injections results from severe insulin deficiency and is commonly used in studies testing glucagon suppression therapy [@bib6], [@bib8] or leptin therapy [@bib13], [@bib20], [@bib32], [@bib33]. Mice were rendered diabetic by STZ injection and treated with Gcgr siRNA (5 mg/kg by tail-vein injection) and/or leptin therapy (20 μg/day by mini-osmotic pump), and FVII siRNA was used as a control, resulting in the following groups: non-diabetic controls, STZ-FVII siRNA, STZ-Gcgr siRNA, STZ-leptin + FVII siRNA, and STZ-leptin + Gcgr siRNA. The leptin + Gcgr siRNA group was nearly identical to the leptin + FVII treated group for all metabolic parameters measured ([Figure 1](#fig1){ref-type="fig"}). As expected, STZ-FVII mice lost weight compared to non-diabetic controls, and neither Gcgr siRNA nor leptin treatment affected body weight ([Figure 2](#fig2){ref-type="fig"}A). While blood glucose was completely normalized by leptin therapy, Gcgr siRNA only modestly reduced fasting blood glucose at this dose (7.3 ± 0.3 mM non-diabetic controls, 29.5 ± 0.6 mM FVII siRNA, 9.9 ± 0.7 mM leptin + FVII siRNA 1, 19.4 ± 0.7 mM Gcgr siRNA, 7.8 ± 1.1 mM leptin + Gcgr siRNA, day 7, P \< 0.05, [Figure 2](#fig2){ref-type="fig"}B). In addition, leptin normalized blood glucose levels following an oral glucose-gavage while Gcgr siRNA caused only a partial improvement ([Figure 2](#fig2){ref-type="fig"}C). However, no differences in glucose excursion were observed between the groups as measured by AUC calculated from baseline ([Figure 2](#fig2){ref-type="fig"}D). All STZ injected groups had plasma insulin levels close to or below the detection limit of the assay (0.019 ng/mL, [Figure 2](#fig2){ref-type="fig"}E). As expected based on [Figure 1](#fig1){ref-type="fig"}E, groups receiving Gcgr siRNA displayed supraphysiological levels of circulating glucagon ([Figure 2](#fig2){ref-type="fig"}F), and groups receiving leptin treatment exhibited supraphysiological levels of plasma leptin ([Figure 2](#fig2){ref-type="fig"}G).Figure 2**Effect of leptin or 5 mg/kg Gcgr siRNA on glucose and lipid metabolism in STZ-diabetic mice.** Insulin deficient diabetes was induced in mice by injecting 180 mg/kg STZ on day −11; vehicle was administered to non-diabetic controls. STZ-diabetic mice were treated with either FVII siRNA, Gcgr siRNA, FVII siRNA + leptin, or Gcgr siRNA + leptin on day 0. siRNA was delivered at a dose of 5 mg/kg via tail-vein injection and leptin was administered at a dose of 20 μg/day via mini-osmotic pump. Body weight (A) and blood glucose (B) were measured throughout the study. On day 6, an oral glucose tolerance test was performed using 1.5 g/kg of 30% dextrose (C), and area under the curve (AUC) from baseline was calculated (D). Plasma levels of insulin (E), glucagon (F), leptin (G), β-hydroxybutyrate (H), fatty acids (I), triglycerides (J), glycerol (K), and cholesterol (L) were analyzed on day 7. Each group was compared to the FVII siRNA treated group by 1- or 2-way ANOVA with Dunnett post-hoc testing; a, P \< 0.05 non-diabetic controls vs FVII siRNA; b, P \< 0.05 Leptin + FVII siRNA vs FVII siRNA; c, P \< 0.05 Gcgr siRNA vs FVII siRNA; d, P \< 0.05 Leptin + Gcgr siRNA vs FVII siRNA. Statistical analysis was not performed on insulin (E) or leptin (G) measurements as some samples were below the limits of detection, denoted by the dotted lines. In addition, five samples had insulin measurements too low to be interpolated and were assigned a value of 0. Data are mean ± SEM (A--C) or min to max box and whisker plots (D--K), n = 7--8.Figure 2

To ascertain how both treatments would affect lipid metabolism, we measured circulating β-hydroxybutyrate, fatty acids, triglycerides, glycerol, and cholesterol ([Figure 2](#fig2){ref-type="fig"}H--L). FVII siRNA treated mice with uncontrolled diabetes displayed elevated β-hydroxybutyrate, which was normalized by both leptin and Gcgr siRNA (0.51 ± 0.04 mM non-diabetic controls, 2.67 ± 0.22 mM FVII siRNA, 0.38 ± 0.03 mM leptin + FVII siRNA, 0.56 ± 0.04 mM Gcgr siRNA, 0.33 ± 0.05 mM leptin + Gcgr siRNA, P \< 0.05, [Figure 2](#fig2){ref-type="fig"}H). Conversely, triglycerides that were raised in the FVII siRNA group were normalized by leptin but unchanged by Gcgr siRNA ([Figure 2](#fig2){ref-type="fig"}J). Interestingly, although plasma fatty acids, glycerol, and cholesterol were not elevated in the FVII siRNA group compared to non-diabetic controls, leptin was capable of reducing all of these parameters, while Gcgr siRNA had no effect on fatty acids or glycerol and modestly raised cholesterol levels ([Figure 2](#fig2){ref-type="fig"}I/K/L). Therefore, while leptin is capable of completely normalizing blood glucose, glucose tolerance, and lipid metabolism, this dose of Gcgr siRNA only partially improved blood glucose and glucose tolerance, fully normalized ketones, had no effect on triglycerides, and increased cholesterol.

3.3. 10 mg/kg Gcgr siRNA reduces blood glucose, increases plasma glucagon, normalizes β-hydroxybutyrate, and increases cholesterol in STZ-diabetic mice {#sec3.3}
-------------------------------------------------------------------------------------------------------------------------------------------------------

Since 5 mg/kg Gcgr siRNA only partially improved glucose homeostasis in STZ-diabetic mice, we investigated if increasing the dose may elicit a more potent effect. Similar to the previous study, compared to non-diabetic controls, STZ caused weight loss in FVII siRNA treated mice, and this was unaffected by Gcgr siRNA ([Figure 3](#fig3){ref-type="fig"}A). While 5 mg/kg Gcgr siRNA reduced blood glucose by 45% by day 7 ([Figure 2](#fig2){ref-type="fig"}B), 10 mg/kg reduced glucose by 76% by day 7 but was still unable to normalize blood glucose ([Figure 3](#fig3){ref-type="fig"}B). For the remainder of the plasma analytes measured, the results were similar to the 5 mg/kg dose of siRNA. STZ injection reduced plasma insulin levels close to or below the limit of detection of the assay (0.019 ng/mL, [Figure 3](#fig3){ref-type="fig"}C). Gcgr siRNA induced supraphysiological levels of circulating glucagon ([Figure 3](#fig3){ref-type="fig"}D). STZ treatment depleted leptin levels in both FVII and Gcgr siRNA treated mice to near the detection limit of the assay ([Figure 3](#fig3){ref-type="fig"}E). β-Hydroxybutyrate levels were increased in FVII siRNA controls and normalized by Gcgr siRNA treatment ([Figure 3](#fig3){ref-type="fig"}F). Triglycerides were elevated in FVII siRNA mice and unchanged due to Gcgr siRNA ([Figure 3](#fig3){ref-type="fig"}H). Fatty acid and glycerol levels were not elevated in FVII siRNA treated controls and remained unchanged due to Gcgr siRNA ([Figure 3](#fig3){ref-type="fig"}G and I). Finally, cholesterol levels were elevated due to Gcgr siRNA compared to FVII siRNA ([Figure 3](#fig3){ref-type="fig"}J). Therefore, 10 mg/kg Gcgr siRNA can lower blood glucose and normalize ketones but does not lower triglycerides and increased cholesterol.Figure 3**10 mg/kg Gcgr siRNA reduces blood glucose, increases plasma glucagon, normalizes β-hydroxybutyrate, and increases cholesterol in STZ-diabetic mice.** Insulin deficient diabetes was induced in mice by injecting 180 mg/kg STZ on day −8; vehicle was administered to non-diabetic controls. On day 0, STZ-diabetic mice were treated with FVII siRNA or Gcgr siRNA at a dose of 10 mg/kg and compared to untreated non-diabetic controls. Body weight (A) and blood glucose (B) were measured throughout the study. Plasma levels of insulin (C), glucagon (D), leptin (E), β-hydroxybutyrate (F), fatty acids (G), triglycerides (H), glycerol (I), and cholesterol (J) were analyzed on day 7. Groups were compared using a 1- or 2-way ANOVA with Tukey post-hoc testing; a, P \< 0.05 non-diabetic controls vs FVII siRNA; b, P \< 0.05 non-diabetic controls vs Gcgr siRNA; c, P \< 0.05 FVII siRNA vs Gcgr siRNA. Statistical analysis was not performed on insulin (C) or leptin (E) measurements as some samples were below the limits of detection, denoted by the dotted lines. In addition, one sample had an insulin measurement too low to be interpolated and was assigned a value of 0. Data are mean ± SEM (A--B) or min to max box and whisker plots (C--I), n = 7--8.Figure 3

3.4. A single injection of 10 mg/kg Gcgr siRNA reduces blood glucose for 3 weeks and improves oral glucose tolerance in STZ-diabetic mice {#sec3.4}
-----------------------------------------------------------------------------------------------------------------------------------------

Next, we assessed how long a single injection of Gcgr siRNA could improve diabetic symptoms in STZ-diabetic mice. Both STZ-injected groups lost weight compared to non-diabetic controls, and Gcgr siRNA treated mice did not differ from FVII siRNA treated mice ([Figure 4](#fig4){ref-type="fig"}A). Gcgr siRNA significantly reduced blood glucose from day 4--29, reaching the lowest value by day 10 (8.2 ± 0.4 mM non-diabetic controls, 23.2 ± 1.6 mM STZ + FVII-siRNA, 10.6 ± 0.4 mM STZ + Gcgr-siRNA, P \< 0.05, [Figure 4](#fig4){ref-type="fig"}B). Gcgr siRNA also improved blood glucose levels throughout an oral glucose tolerance test; however, no statistical differences in AUC measured from baseline were observed between groups ([Figure 4](#fig4){ref-type="fig"}C and D). Therefore, a single injection of Gcgr siRNA was capable of ameliorating blood glucose for over 3 weeks in STZ-diabetic mice.Figure 4**A single injection of 10 mg/kg Gcgr siRNA reduces blood glucose for 3 weeks and improves oral glucose tolerance in STZ-diabetic mice.** Insulin deficient diabetes was induced in mice by injecting 180 mg/kg STZ on day −22; vehicle was administered to non-diabetic controls. STZ-diabetic mice were treated with FVII siRNA or Gcgr siRNA at a dose of 10 mg/kg on day 0 and compared to untreated non-diabetic controls. Body weight (A) and blood glucose (B) were measured throughout the study. On day 10, an oral glucose tolerance test was performed using 1.5 g/kg of 30% dextrose (C), and area under the curve (AUC) from baseline was calculated (D). Groups were compared using a 1- or 2-way ANOVA with Tukey post-hoc testing; a, P \< 0.05 non-diabetic controls vs FVII siRNA; b, P \< 0.05 non-diabetic controls vs Gcgr siRNA; c, P \< 0.05 FVII siRNA vs Gcgr siRNA. Data are mean ± SEM (A--C) or min to max box and whisker plots (D), n = 5.Figure 4

3.5. Leptin therapy does not affect body weight, blood glucose, or oral glucose tolerance in HFD/STZ-diabetic mice {#sec3.5}
------------------------------------------------------------------------------------------------------------------

We next assessed the effectiveness of Gcgr siRNA and leptin therapy in the HFD/STZ mouse model of diabetes. HFD/STZ mice are characterized by insulin resistance resulting from HFD feeding and mild β-cell loss due to a moderate dose of STZ, resembling features of type 2 diabetes [@bib34], [@bib35]. HFD/STZ-diabetic mice were put on a 60% HFD at 6 weeks of age and given 100 mg/kg STZ at 10 weeks of age. At 12 weeks of age, we tested leptin therapy by administering daily i.p. injections of PEG-leptin or vehicle to HFD/STZ mice and compared results to 10% LFD controls. We have previously shown that delivery of leptin via mini-osmotic pump and PEG-leptin by daily i.p. injection similarly lower fasting blood glucose in STZ-diabetic mice [@bib19]. HFD mice were initially heavier than LFD controls; however, following STZ treatment, the body weights converged, and there was no effect of leptin vs vehicle ([Figure 5](#fig5){ref-type="fig"}A). Although fasting blood glucose tended to be lower in the leptin treated group, there was no significant difference between leptin and vehicle treatment (6.9 ± 0.3 mM LFD, 19.3 ± 1.9 mM HFD/STZ + vehicle, 17.1 ± 2.5 mM HFD/STZ + leptin, day 14, P \> 0.05, [Figure 5](#fig5){ref-type="fig"}B). Similarly, although blood glucose values were lower in the leptin treated group than in the vehicle treated group at all time points during the oral glucose tolerance test, there were no significant differences between the groups in the glucose response curves or the AUC ([Figure 5](#fig5){ref-type="fig"}C and D). Plasma insulin levels were variable within each group, and the range of insulin values in the HFD/STZ groups overlapped with the values of the LFD group ([Figure 5](#fig5){ref-type="fig"}E). This leptin injection regimen resulted in extremely high circulating leptin levels (2.9 ± 0.7 ng/mL LFD, 7.5 ± 1.5 ng/mL HFD/STZ + vehicle, 2809.6 ± 259.6 ng/mL HFD/STZ + leptin, day 14, P \> 0.05, [Figure 5](#fig5){ref-type="fig"}F). Therefore, despite supraphysiological leptin levels, leptin did not significantly lower blood glucose levels in the fasting state or following glucose-gavage in HFD/STZ-diabetic mice, contrary to the potent glucose-lowering effect of leptin in STZ diabetic mice ([Figure 2](#fig2){ref-type="fig"}).Figure 5**Leptin therapy does not affect body weight, blood glucose, or oral glucose tolerance in HFD/STZ-diabetic mice.** Mice on a HFD were injected with 100 mg/kg STZ on day −14. Starting on day 0, HFD/STZ-diabetic mice were injected daily with PEG-leptin at a dose of 20 μg/day or vehicle and compared to untreated LFD fed mice. Body weight (A) and blood glucose (B) were measured throughout the study. On day 7, an oral glucose tolerance test was performed using 1.5 g/kg of 30% dextrose (C), and area under the curve (AUC) from baseline was calculated (D). Plasma levels of insulin (E) and leptin (F) were measured on day 14. Groups were compared using a 1- or 2-way ANOVA with Tukey post-hoc testing; a, P \< 0.05 LFD vs vehicle; b, P \< 0.05 LFD vs leptin; c, P \< 0.05 vehicle vs leptin. Statistical analysis was not performed on insulin (E) measurements as some samples were below the limit of detection, denoted by the dotted line, and one sample was too low to be interpolated and was assigned a value of 0. Data are mean ± SEM (A--C) or min to max box and whisker plots (D--E), n = 6--8.Figure 5

3.6. 10 mg/kg Gcgr siRNA reduces blood glucose and improves oral glucose tolerance in HFD/STZ-diabetic mice {#sec3.6}
-----------------------------------------------------------------------------------------------------------

Next, we injected Gcgr siRNA or FVII siRNA at a dose of 10 mg/kg into HFD/STZ to determine if the glucose reducing effect would be as potent as it was in STZ-diabetic mice. The body weights of HFD/STZ-diabetic mice that received Gcgr siRNA were no different than those that received FVII siRNA ([Figure 6](#fig6){ref-type="fig"}A). Remarkably, blood glucose was normalized to that of LFD controls due to Gcgr siRNA treatment (8.7 ± 0.4 mM LFD, 19.5 ± 1.8 mM HFD/STZ + FVII siRNA, 7.4 ± 0.4 mM HFD/STZ + Gcgr siRNA, day 14, P \< 0.05, [Figure 6](#fig6){ref-type="fig"}B). Moreover, blood glucose levels following oral glucose gavage were greatly improved due to Gcgr siRNA compared to FVII siRNA; however, AUC measurements did not differ between the groups ([Figure 6](#fig6){ref-type="fig"}C and D). Next, we measured various plasma analytes to better understand how Gcgr siRNA affected metabolic processes in this model. All groups had many plasma insulin levels close to or below the limit of detection of the assay (0.115 ng/mL) ([Figure 6](#fig6){ref-type="fig"}E). Similar to our previous studies, Gcgr siRNA induced supraphysiological levels of circulating glucagon ([Figure 6](#fig6){ref-type="fig"}F). Plasma leptin, β-hydroxybutyrate, fatty acids, glycerol, and cholesterol were unchanged due to HFD/STZ induced diabetes, and there were no differences between FVII and Gcgr siRNA treated groups ([Figure 6G--I](#fig6){ref-type="fig"},K,L). Lastly, plasma triglycerides were increased in the FVII siRNA group and remained unchanged due to Gcgr siRNA treatment ([Figure 6](#fig6){ref-type="fig"}J). Therefore, not only can Gcgr siRNA improve glucose metabolism in the STZ model of severe insulin deficiency, it can also potently lower blood glucose levels in the fasting state and post-glucose gavage in the HFD/STZ model of type 2 diabetes, although it does not improve plasma triglycerides.Figure 6**10 mg/kg Gcgr siRNA reduces blood glucose and improves oral glucose tolerance in HFD/STZ-diabetic mice.** Mice on a HFD were injected with 100 mg/kg STZ on day −15. HFD/STZ-diabetic mice were treated with FVII siRNA or Gcgr siRNA at a dose of 10 mg/kg on day 0 and compared to untreated LFD fed mice. Body weight (A) and blood glucose (B) were measured throughout the study. On day 6, an oral glucose tolerance test was performed using 1.5 g/kg of 30% dextrose (C), and area under the curve (AUC) from baseline was calculated (D). Plasma levels of insulin (E), glucagon (F), leptin (G), β-hydroxybutyrate (H), fatty acids (I), triglycerides (J), glycerol (K), and cholesterol (L) were analyzed on day 14. Groups were compared using a 1- or 2-way ANOVA with Tukey post-hoc testing; a, P \< 0.05 LFD vs FVII siRNA; b, P \< 0.05 LFD vs Gcgr siRNA; c, P \< 0.05 FVII siRNA vs Gcgr siRNA. Statistical analysis was not performed on insulin (E) measurements as some samples were below the limit of detection, denoted by the dotted line. Data are mean ± SEM (A--C) or min to max box and whisker plots (D--K), n = 7--8.Figure 6

3.7. A single injection of 10 mg/kg Gcgr siRNA reduces blood glucose for 2 months and improves oral glucose tolerance in HFD/STZ-diabetic mice {#sec3.7}
----------------------------------------------------------------------------------------------------------------------------------------------

Because Gcgr siRNA can robustly normalize diabetic symptoms in HFD/STZ mice, we aimed to determine how long a single injection could lower blood glucose in this model. Similar to our previous studies, there were no differences in body weight between Gcgr siRNA and FVII siRNA treated mice ([Figure 7](#fig7){ref-type="fig"}A). Strikingly, fasting blood glucose levels in the Gcgr siRNA treated group were indistinguishable from those in LFD controls for approximately 1 month (8.6 ± 0.5 mM LFD, 16.8 ± 2.4 mM HFD/STZ + FVII siRNA, 8.2 ± 0.9 mM HFD/STZ + Gcgr siRNA, day 30, P \< 0.05) and remained significantly reduced compared to FVII siRNA controls until day 71 ([Figure 7](#fig7){ref-type="fig"}B). Due to the long-term amelioration in blood glucose, we measured HbA1c on day 24 and 48 and found that levels were reduced in mice that received Gcgr siRNA ([Figure 7](#fig7){ref-type="fig"}C and D). On day 6, mice receiving Gcgr siRNA had normalized blood glucose levels during an oral glucose tolerance ([Figure 7](#fig7){ref-type="fig"}E), and this effect waned by day 43 ([Figure 7](#fig7){ref-type="fig"}G). No differences were observed between AUC measurements on either day 6 or 43 between Gcgr siRNA and FVII siRNA treated groups ([Figure 7](#fig7){ref-type="fig"}F and H). Therefore, a single injection of Gcgr siRNA can reduce fasting blood glucose for 2 months, improve oral glucose tolerance, and reduce HbA1c levels in HFD/STZ mice.Figure 7**A single injection of 10 mg/kg Gcgr siRNA reduces blood glucose for 2 months and improves oral glucose tolerance in HFD/STZ-diabetic mice.** Mice on a HFD were injected with 100 mg/kg STZ on day −13. HFD/STZ-diabetic mice were treated with FVII siRNA or Gcgr siRNA at a dose of 10 mg/kg on day 0 and compared to untreated LFD fed mice. Body weight (A) and blood glucose (B) were measured throughout the study. HbA1c was analyzed on day 24 (C) and 48 (D). On day 6, an oral glucose tolerance test was performed using 1.5 g/kg of 30% dextrose (E), and area under the curve (AUC) from baseline was calculated (F). On day 43, an oral glucose tolerance test was performed using 1.5 g/kg of 30% dextrose (G), and area under the curve (AUC) was calculated (H). Groups were compared using a 1- or 2-way ANOVA with Tukey post-hoc testing; a, P \< 0.05 LFD vs FVII siRNA; b, P \< 0.05 LFD vs Gcgr siRNA; c, P \< 0.05 FVII siRNA vs Gcgr siRNA. Data are mean ± SEM (A, B, E, G) or min to max box and whisker plots (C, D, F, H), n = 6--7.Figure 7

4. Discussion {#sec4}
=============

We report that administration of Gcgr siRNA encapsulated in LNPs can reduce blood glucose levels in the fasting state or post-glucose gavage in wildtype mice and dramatically improve glucose metabolism in STZ and HFD/STZ-diabetic mice, models of type 1 and type 2 diabetes [@bib34], [@bib35], respectively. The phenotype in our acute knockdown model closely resembles that of GcgrKO mice, suggesting the highly efficient knockdown of the Gcgr. GcgrKO mice exhibited a ∼30% reduction in blood glucose levels compared to GcgrWT mice [@bib29], while mice receiving Gcgr siRNA exhibited a reduction of ∼40% in blood glucose levels compared to FVII siRNA controls. While GcgrKO mice had an excess of 250-fold higher circulating glucagon levels concomitant with extreme α-cell hyperplasia [@bib29], a ∼5 fold increase in plasma glucagon with no alteration in α-cell area was observed on day 7 of our study. This may reflect the acute nature of our knockdown model and suggests that the rise in circulating glucagon in our study may be due to increased glucagon transcription, translation, and/or secretion, whereas increased α-cell mass likely contributes to hyperglucagonemia in GcgrKO mice. We used C57BL/6J mice, which are known for relatively high fasting blood glucose levels compared to other strains of mice [@bib36]; thus, it is unclear whether Gcgr siRNA would have decreased blood glucose levels to the same extent in other strains.

Following characterization of our knockdown model in wildtype mice, we found that Gcgr siRNA diminished blood glucose levels in the fasting state as well as post-glucose gavage in insulin-deficient STZ-diabetic mice. Increasing the dose of Gcgr siRNA from 5 to 10 mg/kg further improved glucose homeostasis, and a single injection reduced blood glucose for 3 weeks. These results, along with other reports of diabetes normalization or prevention using GcgrKO or glucagon/Gcgr antagonizing antibodies in rodent models of type 1 diabetes, have challenged the insulinocentric dogma of diabetes by suggesting that glucagon excess rather than insulin deficiency is critical for the development of diabetes. However, recent reports demonstrate that as insulin deficiency becomes more severe, glucagon blockage is less efficacious. Steenberg et al. suppressed glucagon action through α-cell ablation by giving diphtheria toxin (DT) to mice expressing diphtheria toxin receptor (DTR) driven by the glucagon promoter, glucagon immunoneutralization, or Gcgr antagonism and found that STZ injection was still capable of inducing hyperglycemia and impaired glucose tolerance [@bib37]. In addition, Damond et al. generated mouse models with more severe insulin deficiency by using a combining STZ injection with insulin receptor antagonism as well as β-cell ablation by giving DT to mice expressing DTR driven by the insulin promoter [@bib38]. When these mice were put on a GcgrKO background or treated with a Gcgr monoclonal antibody, hyperglycemia still developed [@bib38]. Finally, in insulin KO mice completely devoid of insulin, Gcgr gene deletion did not prevent the development of diabetes [@bib39]. Taken together, these studies suggest that sufficient levels of basal insulin may be required for glucagon suppression to be therapeutic for type 1 diabetes.

In addition to lowering blood glucose, Gcgr siRNA also potently suppressed ketones but did not affect lipid metabolism in STZ-diabetic mice. Strikingly, the effect on ketosis may be even more potent than the effect on blood glucose, since the lower dose of siRNA, which only modestly reduced blood glucose, was capable of restoring ketones to control levels. This phenomenon has been observed previously when STZ-diabetic mice were given a GLP-1R agonist or glucagon-neutralizing antibody, which reversed hyperglucagonemia, and blood glucose levels were unchanged while ketones were lowered [@bib40]. However, at both doses of Gcgr siRNA, plasma triglycerides, plasma fatty acids, and glycerol were unchanged, and plasma cholesterol was increased. Interestingly, clinical trials of type 2 diabetic patients receiving Gcgr antagonists [@bib41], [@bib42] as well as a study involving *db/db* mice receiving Gcgr siRNA [@bib11] have reported increased low-density lipoprotein cholesterol (LDL-C). We only observed an increase in total plasma cholesterol due to Gcgr siRNA in STZ-diabetic mice and not HFD/STZ-diabetic mice, but did not measure the individual lipoprotein components. In contrast to Gcgr siRNA treatment, leptin therapy suppressed plasma ketones, fatty acids, triglycerides, glycerol, and cholesterol, consistent with previous studies [@bib13], [@bib14], [@bib17], [@bib18], [@bib20], [@bib32]. Therefore, this suggests that glucagon reduction by leptin may contribute to improving hyperglycemia and ketosis but not to the suppression of lipid metabolism.

Since leptin is a potent glucagon suppressor, it has been postulated that reduced glucagon action contributes to the glucose-lowering effect of leptin therapy in insulin-deficient diabetes [@bib13], [@bib14]. However, several lines of evidence counter this idea. A low dose of leptin in rats normalized plasma glucagon levels but only slightly lowered blood glucose levels [@bib43]. In addition, while leptin treatment in rats normalized blood glucose within 6 h, glucagon was only suppressed by 24 h of leptin therapy, thereby temporally disconnecting the two effects [@bib17]. Finally, the importance of inhibited lipolysis, reduced plasma fatty acids and glycerol, and thus reduced gluconeogenesis underlying the glucose-lowering mechanism of leptin have been demonstrated in mice and rats [@bib17], [@bib18], [@bib32]. We report that fatty acids and glycerol levels are reduced with leptin therapy, but this effect was not seen following injection of Gcgr siRNA. Therefore, while inhibiting glucagon action alone may be beneficial in type 1 diabetes, leptin action exerts additional effects which can reduce hyperglycemia.

After observing the glucose-lowering effect of Gcgr siRNA in STZ diabetes, we sought to determine whether this effect could be extended to a model of type 2 diabetes, the HFD/STZ mouse. Strikingly, a single injection of Gcgr siRNA reduced fasting blood glucose levels for approximately 2 months and improved HbA1c levels in this model. In addition, in contrast to the beneficial effects of leptin monotherapy in STZ-diabetic mice, leptin treatment in HFD/STZ mice did not improve diabetic symptoms. Despite immensely high leptin levels, there was only a trend towards an improvement in blood glucose levels and oral glucose tolerance. Other studies have reported that leptin therapy in HFD/STZ mice caused a partial improvement in blood glucose and glucose tolerance [@bib44], [@bib45]. Discrepancies between these studies and ours may be due to differences in the timing of STZ relative to HFD treatment, the dose of STZ, the % of fat in the diet, or the method of leptin delivery [@bib44], [@bib45]. Nonetheless, a dose of leptin that would have normalized hyperglycemia in STZ diabetic mice does not normalize diabetic symptoms in HFD/STZ diabetic mice, possibly due to leptin resistance. Similar to obese humans with type 2 diabetes, HFD/STZ mice exhibited 2.5-fold elevated leptin levels compared to LFD controls, which may suggest leptin resistance. Several pre-clinical studies have identified strategies to enhance endogenous leptin sensitivity [@bib44], [@bib46], [@bib47], [@bib48], [@bib49], [@bib50] which may help overcome leptin resistance and unleash the body weight and blood glucose lowering effects of leptin.

Liver specific suppression of glucagon action may be more beneficial than whole body inhibition in treating metabolic disease. Liver specific *GcgrKO* mice exhibit improvements in fasting blood glucose and glucose tolerance to the same degree as that seen in whole body *GcgrKO* mice [@bib29], [@bib30], highlighting the importance of glucagon action on the liver and glucose homeostasis. Interestingly, outside the liver, glucagon can exert beneficial effects in the brain by inhibiting glucose production, improving glucose tolerance [@bib51], promoting satiety, and increasing energy expenditure, in the muscle by promoting glucose uptake, and in WAT by increasing lipolysis [@bib52], [@bib53]. Therefore, administration of Gcgr siRNA, which largely targets the liver and increases circulating glucagon levels, could elicit added benefits of extra-hepatic glucagon signaling compared to a Gcgr antagonist targeting glucagon receptors throughout the body.

Taken together, our results indicate that Gcgr siRNA encapsulated in LNPs is an effective therapy in mouse models of type 1 and type 2 diabetes. Utilization of small molecule Gcgr antagonists for the treatment of glycemic control has been of interest and is currently in phase 2 clinical trials for patients with type 2 diabetes ([clinicaltrials.gov](http://clinicaltrials.gov){#intref0010}, [NCT02851849](ctgov:NCT02851849){#intref0015}). In addition, LNP delivery of siRNA is currently in clinical trials for the treatment of various liver-related diseases. Therefore, Gcgr siRNA delivery via LNPs may hold therapeutic potential for the treatment of diabetes in humans.
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